UCB 'on the road again'
Posted by
13-Sep-2011
We’re hitting the road this month to update investors on our latest half-year results and the financial outlook for the future.
Now that the summer is behind us, it’s a great time to catch up with investors and discuss the performance of our core medicines, which are on their way to reach the communicated peak sales guidance, as well as what the clinical pipeline has in store.
This is something we like to do regularly as part of our efforts to inform investors and shareholders, as well as taking the opportunity to listen to the interests of the investment community.
Our tour will be a mix of individual and group meetings and so-called fire-side chats with investors in key financial capitals.
The first stop is New York where we’ll spend September 13 and 14, before flying to London for September 15. Then it’s on to Dusseldorf on September 20th, back to London for the 28th, before rounding things off in Paris on the 29th.
Looks like a busy couple of weeks but we’re really looking forward to getting the conversation started again after the summer break.
Now that the summer is behind us, it’s a great time to catch up with investors and discuss the performance of our core medicines, which are on their way to reach the communicated peak sales guidance, as well as what the clinical pipeline has in store.
This is something we like to do regularly as part of our efforts to inform investors and shareholders, as well as taking the opportunity to listen to the interests of the investment community.
Our tour will be a mix of individual and group meetings and so-called fire-side chats with investors in key financial capitals.
The first stop is New York where we’ll spend September 13 and 14, before flying to London for September 15. Then it’s on to Dusseldorf on September 20th, back to London for the 28th, before rounding things off in Paris on the 29th.
Looks like a busy couple of weeks but we’re really looking forward to getting the conversation started again after the summer break.
Leave a Comment